STUDY OBJECTIVES:Obstructive sleep apnea (OSA) promotes myocardial electrical instability and may predispose to nocturnal sudden cardiac death. We evaluated whether hypobaric hypoxia during altitude travel further impairs cardiac repolarization in patients with OSA, and whether this is prevented by acetazolamide, a drug known to improve oxygenation and central sleep apnea at altitude. METHODS: Thirty-nine OSA patients living < 600 m, discontinued continuous positive airway pressure therapy during studies at 490 m and during two sojourns of 3 days at altitude (2 days at 1860 m, 1 day at 2590 m). During one altitude sojourn, patients took acetazolamide, during the other placebo, or vice versa, according to a randomized, double-blind crossover design. Twelve-lead electrocardiography and pulse oximetry (SpO2) were recorded during nocturnal polysomnography. Heart rate corrected mean QT intervals during the entire night (meanQTc) and during 1 min of the night with the longest meanQTc (maxQTc) were determined. RESULTS: At 490 m the median nocturnal SpO2 was 93%, medians of meanQTc and maxQTc were 420 ms and 478 ms. At 2590 m, on placebo, SpO2 was lower (85%), and meanQTc and maxQTc were prolonged to 430 ms and 510 ms (P < 0.02 vs. 490 m, all corresponding comparisons). At 2590 m on acetazolamide, median SpO2 was increased to 88% (P < 0.05 vs. placebo), meanQTc was reduced to 427 ms (P < 0.05 vs. placebo), whereas maxQTc remained increased at 502 ms (P = ns vs. placebo). CONCLUSIONS: At 2590 m OSA patients experienced cardiac repolarization disturbances in association with hypoxemia. Prolongation of meanQTc at altitude was prevented and hypoxemia was improved by acetazolamide, whereas maxQTc remained increased suggesting imperfect protection from repolarization disturbances. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID: NTC-00714740. URL: www.clinicaltrials.gov.
RCT Entities:
STUDY OBJECTIVES:Obstructive sleep apnea (OSA) promotes myocardial electrical instability and may predispose to nocturnal sudden cardiac death. We evaluated whether hypobaric hypoxia during altitude travel further impairs cardiac repolarization in patients with OSA, and whether this is prevented by acetazolamide, a drug known to improve oxygenation and central sleep apnea at altitude. METHODS: Thirty-nine OSA patients living < 600 m, discontinued continuous positive airway pressure therapy during studies at 490 m and during two sojourns of 3 days at altitude (2 days at 1860 m, 1 day at 2590 m). During one altitude sojourn, patients took acetazolamide, during the other placebo, or vice versa, according to a randomized, double-blind crossover design. Twelve-lead electrocardiography and pulse oximetry (SpO2) were recorded during nocturnal polysomnography. Heart rate corrected mean QT intervals during the entire night (meanQTc) and during 1 min of the night with the longest meanQTc (maxQTc) were determined. RESULTS: At 490 m the median nocturnal SpO2 was 93%, medians of meanQTc and maxQTc were 420 ms and 478 ms. At 2590 m, on placebo, SpO2 was lower (85%), and meanQTc and maxQTc were prolonged to 430 ms and 510 ms (P < 0.02 vs. 490 m, all corresponding comparisons). At 2590 m on acetazolamide, median SpO2 was increased to 88% (P < 0.05 vs. placebo), meanQTc was reduced to 427 ms (P < 0.05 vs. placebo), whereas maxQTc remained increased at 502 ms (P = ns vs. placebo). CONCLUSIONS: At 2590 m OSA patients experienced cardiac repolarization disturbances in association with hypoxemia. Prolongation of meanQTc at altitude was prevented and hypoxemia was improved by acetazolamide, whereas maxQTc remained increased suggesting imperfect protection from repolarization disturbances. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID: NTC-00714740. URL: www.clinicaltrials.gov.
Authors: Buddha Basnyat; Jeffrey H Gertsch; E William Johnson; Franco Castro-Marin; Yoshio Inoue; Clement Yeh Journal: High Alt Med Biol Date: 2003 Impact factor: 1.981
Authors: Pentti M Rautaharju; Borys Surawicz; Leonard S Gettes; James J Bailey; Rory Childers; Barbara J Deal; Anton Gorgels; E William Hancock; Mark Josephson; Paul Kligfield; Jan A Kors; Peter Macfarlane; Jay W Mason; David M Mirvis; Peter Okin; Olle Pahlm; Gerard van Herpen; Galen S Wagner; Hein Wellens Journal: J Am Coll Cardiol Date: 2009-03-17 Impact factor: 24.094
Authors: Abhimanyu Uberoi; Ricardo Stein; Marco V Perez; James Freeman; Matthew Wheeler; Frederick Dewey; Roberto Peidro; David Hadley; Jonathan Drezner; Sanjay Sharma; Antonio Pelliccia; Domenico Corrado; Josef Niebauer; N A Mark Estes; Euan Ashley; Victor Froelicher Journal: Circulation Date: 2011-08-09 Impact factor: 29.690
Authors: Tsogyal D Latshang; Yvonne Nussbaumer-Ochsner; Rahel M Henn; Silvia Ulrich; Christian M Lo Cascio; Bruno Ledergerber; Malcolm Kohler; Konrad E Bloch Journal: JAMA Date: 2012-12-12 Impact factor: 56.272
Authors: Hannes Hudalla; Zoe Michael; Nicolas Christodoulou; Gareth R Willis; Angeles Fernandez-Gonzalez; Evgenia J Filatava; Paul Dieffenbach; Laura E Fredenburgh; Robert S Stearman; Mark W Geraci; Stella Kourembanas; Helen Christou Journal: Am J Respir Cell Mol Biol Date: 2019-10 Impact factor: 7.748
Authors: Michael Furian; Deborah Flueck; Tsogyal D Latshang; Philipp M Scheiwiller; Sebastian Daniel Segitz; Séverine Mueller-Mottet; Christian Murer; Adrian Steiner; Silvia Ulrich; Thomas Rothe; Malcolm Kohler; Konrad E Bloch Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-10-26
Authors: Maya Bisang; Tsogyal D Latshang; Sayaka S Aeschbacher; Fabienne Huber; Deborah Flueck; Mona Lichtblau; Stefanie Ulrich; Elisabeth D Hasler; Philipp M Scheiwiller; Silvia Ulrich; Konrad E Bloch; Michael Furian Journal: Front Med (Lausanne) Date: 2021-03-01